We use cookies to provide the content and functionality of this website, and subject to your consent, to analyze the use of our website and to ensure you get the best experience. Third parties with whom we collaborate can also install cookies in order to show you personalized advertisements on other websites. Read our cookie notice for more information

Breaking down Barriers to Precision Medicine

Expanding the reach of precision medicine by providing unprecedented resolution into disease-defining biology from a blood test.

ABOUT US

We've developed a platform that uncovers the activation status of therapeutically actionable genes and pathways from a simple blood test. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.

our SCIENCE

Our first-in-class liquid biopsy platform profiles circulating chromatin and the DNA methylome from just 1mL of plasma. This genome-wide, feature-rich space of ~20K gene promoters, ~1M gene enhancers, and ~50K CpG islands gives us resolution into the dynamic activation of individual genes and pathways.

Our first-in-class comprehensive epigenomic liquid biopsy platform profiles circulating chromatin and the DNA methylome from just 1mL of plasma. This genome-wide, feature-rich space of ~20K gene promoters, ~1M gene enhancers, and ~50K CpG islands gives us resolution into the dynamic activation of individual genes and pathways.

01

02

03

04

05

It starts in the clinic with a simple blood draw

We profile transcriptional biology using sophisticated molecular techniques

And apply proprietary machine learning approaches

To give you interpretable and actionable readouts

Expanding the universe of precision medicine

Expanding the universe of precision medicine

our Team

Experts in the fields of liquid biopsy development, computational biology, epigenomics, and the translational sciences.

leadership

Team

sab

bod

Investors

leadership

J. Carl Barrett, PhD

J. Carl Barrett, PhD

Chief Scientific Officer

Juliann Chmielecki, PhD

Juliann Chmielecki, PhD

Vice President, Translational Sciences

Kristian Cibulskis

Kristian Cibulskis

Senior Director, Head of Bioinformatics Engineering

Travis Clark, PhD

Travis Clark, PhD

Vice President, Product Development

Matthew Eaton, PhD

Matthew Eaton, PhD

Vice President, Computational Biology

Jennifer Fortune, PhD

Jennifer Fortune, PhD

Chief Operating Officer

Josephine N. Harada, MBA, PhD

Josephine N. Harada, MBA, PhD

Vice President, Corporate and Business Development

Eric Kaldjian, MD

Eric Kaldjian, MD

Medical Advisor

Adrian Li, PhD

Adrian Li, PhD

Associate Director, Corporate Strategy and Operations

Geoff Otto, PhD

Geoff Otto, PhD

Chief Product Development Officer

Corrie Painter, PhD

Corrie Painter, PhD

Vice President, External Research and Partnerships

Fernando Ramirez

Fernando Ramirez

Director, Head of Lab Automation

Wendy Rieder, JD

Wendy Rieder, JD

General Counsel

Grace Tkach

Grace Tkach

Head of People

Rehan Verjee

Rehan Verjee

Co-Founder, Chief Executive Officer, Board Director

TEAM

Bhish Amlani, PhD

Senior Director, Scientific Strategy and Operations

Jonathan Beagan, PhD

Scientist, Computational Biology & Bioinformatics

Michael Coyne, MS

Associate Director, Development Operations

Anthony D'Ippolito, PhD

Senior Scientist, Computational Biology & Bioinformatics

Amy Donahue, MS

Senior Scientist, Product Development

Justin Finkle

Senior Scientist, Computational Biology & Bioinformatics

Garrett Gilman

Associate Director, Operations & Facilities

Aparna Gorthi, PhD

Associate Director, Translational Sciences

Mandy Greene

Senior Scientist, Product Development

Jamey Guess, MS

Senior Scientist, Computational Biology & Bioinformatics

Sarah Kieft

Senior Research Associate, Development Operations

Alyssa Lau, PhD

Senior Scientist, Product Development

Mary McGillicuddy

Senior Clinical Project Manager

Brigitte Mottla

Executive Assistant

Anatoly Myaskovsky

Senior Automation Engineer, Product Development

Khoi Nguyen

Senior Scientist, Computational Biology

Charlene O'Brien

Scientist, Development Operations

David Rawling, PhD

Principal Scientist, Product Development

Hathairat Sawaengsri, PhD

Associate Director, Clinical Program Management

Tyrone Tamakloe

Scientist, Development Operations

Baovy Tran

Scientist, Development Operations

Jenna Wurster, PhD

Scientist, Computational Biology and Bioinformatics

Mike Zhong, MS

Principal Software Engineer

Scientific Advisory BoarD

Sylvan Baca, MD, PhD

Co-Founder of Precede; Assistant Professor of Medicine, Dana-Farber Cancer Institute

Sylvan Baca, MD, PhD

Co-Founder of Precede; Assistant Professor of Medicine, Dana-Farber Cancer Institute

Close Button

Toni Choueiri, MD

Co-Founder of Precede; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute

Toni Choueiri, MD

Co-Founder of Precede; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute

Close Button

Matthew Freedman, MD

Co-Founder of Precede; Professor of Medicine, Dana-Farber Cancer Institute

Matthew Freedman, MD

Co-Founder of Precede; Professor of Medicine, Dana-Farber Cancer Institute

Close Button

Richard B. Lanman, MD

President, Institute for Historical Ecology; Previously Global CMO Guardant Health; Past Chief Medical Officer at Veracyte, diaDexus, and Atherotech

Richard B. Lanman, MD

President, Institute for Historical Ecology; Previously Global CMO Guardant Health; Past Chief Medical Officer at Veracyte, diaDexus, and Atherotech

Close Button

Doron Lipson, PhD

CSO at Ultima Genomics; Previously VP of Clinical Product Development at Foundation Medicine

Doron Lipson, PhD

CSO at Ultima Genomics; Previously VP of Clinical Product Development at Foundation Medicine

Close Button

Joseph Loscalzo, MD, PhD

Professor of Theory and Practice of Medicine, HMS; Chairman of Department of Medicine, Brigham and Women’s Hospital

Joseph Loscalzo, MD, PhD

Professor of Theory and Practice of Medicine, HMS; Chairman of Department of Medicine, Brigham and Women’s Hospital

Close Button

Daniel Marshak, PhD

Previously CSO, PerkinElmer

Daniel Marshak, PhD

Previously CSO, PerkinElmer

Close Button

Olga Troyanskaya, PhD

Professor of Computer Science and Genomics, Princeton University

Olga Troyanskaya, PhD

Professor of Computer Science and Genomics, Princeton University

Close Button

Board of Directors

Judith Li, MBA

Partner, Lilly Asia Ventures

Judith Li, MBA

Partner, Lilly Asia Ventures

Alex Parker, PhD

Independent Advisor; Previously Vice President, Business Development, Foundation Medicine

Alex Parker, PhD

Independent Advisor; Previously Vice President, Business Development, Foundation Medicine

Kush Parmar, MD, PhD

Managing Partner, 5AM Ventures

Kush Parmar, MD, PhD

Managing Partner, 5AM Ventures

Rehan Verjee

Co-Founder, Chief Executive Officer, Board Director

Rehan Verjee

Co-Founder, Chief Executive Officer, Board Director

Rehan is the founding CEO of Precede Biosciences. Prior to co-founding Precede Bio, Rehan was a member of the Healthcare Executive Committee at Merck KGaA from October 2015 to March 2021. During this time, Rehan served as the President of EMD Serono and as the Chief Marketing and Strategy officer. In these roles, Rehan was responsible for growing the global, multi-billion dollar specialty medicine franchises of oncology, neurology, immunology and infertility, which included leading and transforming the North American business, co-chairing the R&D development committee (responsible for all R&D decisions from Phase 1 to approval), leading global business development, chairing significant global R&D alliances, and having responsibility for the launches of new medicines across the major markets of the USA, the EU, China and Japan. Rehan is currently a member of the board of directors of Tyra Biosciences and the Massachusetts Biotechnology Council, and he holds a Master's degree in Molecular and Cellular Biochemistry from the University of Oxford in the U.K.

Richard Young, PhD

Member, Whitehead Institute; Professor of Biology, MIT

Richard Young, PhD

Member, Whitehead Institute; Professor of Biology, MIT

Investors

Dana-Farber Logo
5am Ventures Logo
Bristol Myers Squibb Logo
Illumina Ventures Logo
OUP Logo
Lilly Asia Ventures Logo
Qatar Investment Authority Logo

PARTNER WITH US

We are actively working with developers of new medicines to elucidate the biology behind treatment response and resistance and to identify new targets that are mechanistically linked to disease.

If you think our platform could make a difference to your medicine in development or your research problem, get in touch with us.

JOIN US

At Precede Biosciences, we believe hard problems are best solved by mission-driven colleagues who trust and genuinely care about one another. We also believe that every person on the team is essential to our success and that every one of us has the potential to change the fabric of the company, and the world, for the better. If this resonates, and you think you can contribute, then apply to an open position.

A wave of water

News

Press Releases

Publications

PRESENTATIONS

Press releases

Publications

Presentations

Get in touch

1 Design Center Place, Suite 19-500, Boston, MA 02210

617.356.1457

We use cookies to provide the content and functionality of this website, and subject to your consent, to analyze the use of our website and to ensure you get the best experience. Third parties with whom we collaborate can also install cookies in order to show you personalized advertisements on other websites. Read our cookie notice for more information